In preeclampsia, FKBPL and its target protein, CD44, have demonstrated their predictive and diagnostic biomarker potential, likely reflective of the pathogenesis of preeclampsia and placental hypoxia (34, 35). Here, FKBPL is linked to preeclampsia.